ストックスクリーナーアプリを入手
15.84
2.64%
-0.43
プレマーケット:
16.29
0.45
+2.84%
前日終値:
$16.27
開ける：
$16.11
24時間の取引高:
17.19M
Relative Volume:
0.82
時価総額：
$3.61B
収益：
$1.78B
当期純損益:
$164.40M
株価収益率:
22.96
EPS:
0.69
ネットキャッシュフロー:
$236.51M
1週間 パフォーマンス:
-5.09%
1か月 パフォーマンス:
-49.52%
6か月 パフォーマンス:
-64.88%
1年 パフォーマンス:
-72.92%
1日の値動き範囲:
$15.57
$16.40
1週間の範囲:
$15.57
$16.96
52週間の値動き範囲:
$15.57
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
15.84 | 3.70B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.54 | 57.69B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
129.13 | 53.00B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.22 | 50.01B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.11 | 40.08B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.05 | 20.77B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Analysis-Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders - WKZO
Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider - Barron's
Hims & Hers Jumps Premarket After $1.15B Global Expansion Deal - Tokenist
Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal - The Wall Street Journal
Hims & Hers stock rises after agreement to acquire Eucalyptus - Investing.com UK
Hims & Hers to buy Aussie digital health firm (HIMS:NYSE) - Seeking Alpha
HIMS Acquires Eucalyptus in Deal Worth Up to $1.15 Billion - GuruFocus
Hims & Hers (HIMS) Plans Major Expansion with Eucalyptus Acquisi - GuruFocus
Hims & Hers to Acquire Eucalyptus in Global Expansion - TipRanks
Hims & Hers Health Makes Australia, Japan Foray With $1.15 Billion Eucalyptus Acquisition - Stocktwits
Hims & Hers to Acquire Eucalyptus in Deal Valued Up to $1.15 Billion - TradingView
Hims & Hers Health to acquire Australia's Eucalyptus for up to $1.15 billion - Reuters
Hims & Hers Health to Acquire Australia's Eucalyptus for up to $1.15 Billion - U.S. News & World Report
Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders - Reuters
Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform - Hims Investor Relations
How We’re Becoming the Leading Global Consumer Health Platform - Hims & Hers Newsroom
Hims & Hers under fire over copycat weight loss drugs - The Hill
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts - Yahoo Finance Singapore
Is Hims & Hers Health Inc Gaining or Losing Market Support? - Benzinga
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Hims And Hers Weighs Legal Risks Against Growth In Longevity Pivot - Yahoo Finance
Hims stock hits 52-week low at 15.62 USD - Investing.com India
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings (NYSE:HIMS) - Seeking Alpha
Do You Think Hims & Hers Health (HIMS) is Positioned for Long-Term Growth? - Insider Monkey
Pre-Market: HIMS (Hims & Hers NYSE) $16.27 on 18 Feb 2026: earnings in focus - Meyka
Deutsche Bank Cite Near-Term Growth Concerns For Hims & Hers Health, Inc. (HIMS) Following GLP-1 Launch Reversal - Finviz
How Ozempic Brought a Napster Moment to Big Pharma - The Wall Street Journal
Market Whales and Their Recent Bets on HIMS Options - Benzinga
Novo Nordisk Patent Fight With Hims And Hers Puts Valuation In Focus - Yahoo Finance
Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month’s 48% Selloff - 24/7 Wall St.
Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out for - Finviz
Hims & Hers Health Stock (HIMS) Opinions on Earnings Beat - Quiver Quantitative
Short Sellers Target Hims & Hers Amid Regulatory and Legal Challenges - AD HOC NEWS
Hims & Hers Health (HIMS) to Release Earnings on Monday - MarketBeat
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’ - AOL.com
Hims & Hers is a brave bet on solving disrupter’s dilemma - Financial Times
Hims & Hers (HIMS) soars 16% on bullish analyst outlook - MSN
Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of "Hold" by Brokerages - MarketBeat
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows - WHTC
Hims & Hers Health Inc (HIMS) Stock Price, Quote, News & History - Benzinga
Hims & Hers Health (HIMS) Is Down 29.2% After Semaglutide Lawsuit And DOJ ReferralHas The Bull Case Changed? - Yahoo Finance
Hims & Hers Health (HIMS) Faces Legal and Market Challenges - GuruFocus
Hims & Hers (HIMS) Faces High Short Interest Amid FDA Speculatio - GuruFocus
Hims and Hers Health (HIMS) Sees Bullish Options Activity with S - GuruFocus
Hims & Hers Unveils New Health Offerings Amid Patent Disputes - timothysykes.com
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know - Finviz
Hims & Hers Falls Over 50% as Novo Files Obesity Lawsuit - GuruFocus
Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More - Benzinga
HIMS Stock Sees Bullish Options Activity with Earnings on the Horizon - GuruFocus
Hims & Hers short interest climbs amid legal risk related to weight loss pill - Seeking Alpha
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.32%
大文字化:
|
ボリューム (24 時間):